Strides Pharma Science Limited has informed the Exchange regarding a press release dated March 05, 2024, titled "Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg".
Press Release Mar 05 2024
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Press Release Jan 30 2024
- Press Release Jan 25 2024
- Press Release Dec 01 2023
- Press Release Nov 23 2023
- Press Release Nov 21 2023
Later from Strides Pharma Science
- Strides Pharma Science Ltd Press Release Apr 09 2024
- Press Release May 10 2024
- Intimation of Board Meeting scheduled on May 22, 2024
- Press Release May 22 2024
- Intimation of Board Meeting scheduled on July 29, 2024
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science